RESEARCH INTEREST
The department has several lines of research. Below are past, current, and future projects:
1.1. Safety: Ongoing ILO clinical trial. Sponsor: HNJ. Eudra CT 2023-503958-12-00.
1.2. Efficacy: CompITO clinical trial, starting in 2025. Sponsor: HNJ, FIS PI24_01770. Clinical trials: NCT06976775
1.3. Efficacy: AlerITO longitudinal cohorts study. Sponsor: Hospital de la Princesa and HNJ. Clinical trials: NCT07419243
1.4. Mechanisms of peanut immunotherapy: study of the oral microbiota. Sponsor: La Princesa Hospital and McMaster University, Canada.
1.5. In peanut allergy: Phase III clinical trial VITESSE clinical trial, and COMFORT clinical trial. Sponsor: DBV (industry).
2.2 Participants in the BANA study, a branch of contract FIS PI21/00158, analysis phase.
2.3 Participants in the study on anaphylaxis versus non-anaphylactic allergy: contract PI24/00360, ongoing.
3.1. Microbiota and food immunotherapy (milk and egg allergy). PI25/00477. Sponsor: Hospital de la Princesa and HNJ.
3.2. BIOPAL study, PI20/01366; principal investigator: Dr. Ibáñez. Currently under analysis.
3.3.- Design of a new diagnostic strategy to identify endotypes of food protein-induced enterocolitis syndrome (FPIES), based on systems biology: Grant application submitted to AES2025, PI25/01583.
4.- Respiratory allergy:
4.1.- NAVIGAIT project: multicenter interventional adherence trial. clinical trials: NCT07419230. Sponsor: HNJ
4.2.- International CHOICE project: currently under analysis. Key group members.
4.3. Artificial Inteligence database analysis for the Severe Asthma Unit.
4.4. Clinical trial on severe asthma and biologic therapy (tezepelumab): Horizon trial.
4.5. Clinical trial on severe asthma and biologic therapy (dupilumab).
Asma, Reacciones Adversas y Alérgicas (ARADYAL).Understanding and predicting interventions. RD16/0006/0026. ISCIII. 2017-2020.
Estudio de la microbiota intestinal en lactantes con alergia a leche de vaca, sus madres y sus abuelas. PI17/01087. ISCIII. 2018-2020.
Investigación vascular en respuesta a anafilaxia y reacciones alérgicas graves.
Benedé S, Pérez-Rangel I, Lozano-Ojalvo D, Molina E, Ibañez MD, López-Fandiño R, López-Expósito I. Anaphylaxis Induced by a Drug Containing Lysozyme and Papain: Influence of Papain on the IgE Response. Int. Arch. Allergy Immunol. 2014. 165: 83-90. FI: 2,673(Q2). PMID: 25359082. DOI: 10.1159/000366101.
Ruiz-García M, Díez CE, García SS, del Río PR, Ibáñez MD. Diagnosis and natural history of food protein-induced enterocolitis syndrome in children from a tertiary hospital in central Spain.. J. Invest. Allergol. Clin. Immunol. 2014. 24: 354-356. FI: 2,596(Q2). PMID: 25345307.
Rodríguez del Río P, Díaz-Perales A, Sanchez-García S, Escudero C, do Santos P, Catarino M, Ibañez MD. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J. Invest. Allergol. Clin. Immunol. 2014. 24: 240-248. FI: 2,596(Q2). PMID: 25219106.
Gámez C, Zafra M, Boquete M, Sanz V, Mazzeo C, Ibáñez MD, Sánchez-García S, Sastre J, del Pozo V. New shrimp IgE-binding proteins involved in mite-seafood cross-reactivity. Mol Nutr Food Res 2014. 58: 1915-1925. FI: 4,603(Q1). PMID: 24978201. DOI: 10.1002/mnfr.201400122.
Sánchez-García S, Rodríguez del Río P, Escudero C, García-Fernández C, Ibáñez MD. Exercise-induced bronchospasm diagnosis in children. Utility of combined lung function tests.. Pediatr Allergy Immunol 2015. 26: 73-79. FI: 3,397(Q1). PMID: 25444583. DOI: 10.1111/pai.12319.
